Table 2.
Treatment and Outcome of Pyomyositis and Infectious Myositis
| Treatment and Outcome Information | Staphylococcal Species (N = 28) | Streptococcal Species (N = 7) | Culture-Negative (N = 16) | Other (N = 10) | Total (N = 61) | P Value |
|---|---|---|---|---|---|---|
| Length of hospital stay in days (median, range) | 13 (2–57) | 10 (0–24) | 6 (1–13) | 8 (5–46) | 9 (0–57) | .05a |
| Length of antimicrobial therapy in days (median, range) | 32 (3–183) | 9 (6–28) | 15 (2–43) | 22 (5–221) | 18 (2–221) | .04a |
| Antimicrobial Therapy | ||||||
| Beta-lactams (No., %) | 18 (64%) | 6 (86%) | 12 (75%) | 4 (40%) | 40 (66%) | .24b |
| Vancomycin (No., %) | 11 (39%) | 1 (14%) | 14 (88%) | 2 (20%) | 28 (46%) | <.00b |
| Fluoroquinolones (No., %) | 0 | 1 (14%) | 2 (13%) | 1 (10%) | 4 (7%) | .11b |
| Tetracyclines (No., %) | 3 (11%) | 0 | 2 (13%) | 1 (10%) | 6 (10%) | 1.00b |
| Trimethoprim-sulfamethoxazole (No., %) | 9 (32%) | 1 (14%) | 2 (13%) | 4 (40%) | 16 (26%) | .35b |
| Received >1 class of antibiotic (No., %) | 11 (39%) | 2 (29%) | 14 (88%) | 3 (30%) | 30 (49%) | .003b |
| Other class of antimicrobial agentc (No., %) | 5 (18%) | 1 (14%) | 6 (38%) | 4 (40%) | 16 (26%) | .32b |
| Adverse events related to antimicrobial therapy (No., %) | 7 (25%) | 0 | 2 (13%) | 1 (10%) | 10 (16%) | .49b |
| Documented nonadherence or left hospital AMA (No., %) | 2 (7%) | 1 (14%) | 1 (6%) | 1 (10%) | 5 (8%) | .84b |
| Surgical Intervention | ||||||
| Incision and drainage (No., %) | 13 (46%) | 3 (43%) | 2 (13%) | 4 (40%) | 22 (36%) | .13b |
| Interventional radiology drainage (No., %) | 15 (54%) | 2 (29%) | 1 (6%) | 4 (40%) | 22 (36%) | .01b |
| Multiple procedures required (No., %) | 11 (39%) | 2 (29%) | 1 (6%) | 3 (30%) | 17 (28%) | .10b |
| Treatment Outcomes | ||||||
| Success (No., %) | 25 (89%) | 6 (86%) | 15 (94%) | 5 (50%) | 51 (84%) | .03b |
Abbreviations: AMA, against medical advice.
aOne-way analysis of variance.
bFisher’s exact test.
cIncludes other antibiotic classes (eg, daptomycin), antivirals, antifungals, etc.